Therapeutic Area: Oncology
Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
Miller et al.
Nature Immunology
March 2019
Authors and Affiliates
Miller BC1,2,3,4,5, Sen DR1,3,6, Al Abosy R1,3, Bi K1,3, Virkud YV7, LaFleur MW1,3,4,5,6, Yates KB1,3, Lako A8, Felt K8, Naik GS8, Manos M2,8, Gjini E2,8, Kuchroo JR4,5,6, Ishizuka JJ1,2,3, Collier JL1,3,4,5,6, Griffin GK1,3,9, Maleri S4,5, Comstock DE1,3,6, Weiss SA1,3,6, Brown FD1,3,4,5,6, Panda A1,3, Zimmer MD3, Manguso RT3, Hodi FS2,8, Rodig SJ8,9, Sharpe AH3,4,5,6, Haining WN10,11,12
1
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
2
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
3
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
4
Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
5
Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
6
Division of Medical Sciences, Harvard Medical School, Boston, MA, USA.
7
Division of Pediatric Allergy and Immunology, Massachusetts General Hospital, Boston, MA, USA.
8
Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
9
Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
10
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. wnhaining@gmail.com.
11
Broad Institute of MIT and Harvard, Cambridge, MA, USA. wnhaining@gmail.com.
12
Division of Medical Sciences, Harvard Medical School, Boston, MA, USA. wnhaining@gmail.com
Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases
Fischer et al.
Cancer Discovery
February 2019
Authors and Affiliates
Fischer GM1,2,3, Jalali A4, Kircher DA5, Lee WC6, McQuade JL2, Haydu LE7, Joon AY8, Reuben A9, de Macedo MP10, Carapeto FCL3, Yang C11, Srivastava A12, Ambati CR13,14, Sreekumar A13,14, Hudgens CW3, Knighton B2, Deng W2, Ferguson SD15, Tawbi HA2, Glitza IC2, Gershenwald JE1,7, Vashisht Gopal YN2,3, Hwu P2, Huse JT3,16, Wargo JA6,7, Futreal PA6, Putluri N13,14, Lazar AJ3,6,16, DeBerardinis RJ11,17, Marszalek JR18, Zhang J6, Holmen SL5,19, Tetzlaff MT3,16, Davies MA20,3,21
1
Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
2
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
3
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
4
Department of Neurosurgery, Baylor College of Medicine, Houston, Texas.
5
Department of Oncological Sciences, University of Utah Health Sciences Center, Salt Lake City, Utah.
6
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
7
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
8
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
9
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
10
Department of Pathology, A.C. Camargo Cancer Center, São Paulo, Brazil.
11
Children's Medical Research Institute, The University of Texas Southwestern Medical Center, Dallas, Texas.
12
Department of Computational Sciences, The Jackson Lab for Genomic Medicine, Farmington, Connecticut.
13
Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, Texas.
14
Advanced Technology Core, Alkek Center for Molecular Discovery, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas.
15
Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
16
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
17
Howard Hughes Medical Institute, The University of Texas Southwestern Medical Center, Dallas, Texas.
18
Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas.
19
Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, Utah.
20
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. mdavies@mdanderson.org.
21
Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Tumor-infiltrating human CD4 regulatory Tcells display a distinct TCR repertoire and exhibit tumor and neoantigen reactivity
Ahmadzadeh et al.
Science Immunology
January 2019
Authors and Affiliates
Ahmadzadeh M1, Pasetto A1, Jia L1, Deniger DC1, Stevanović S2, Robbins PF1, Rosenberg SA3.
1
Surgery Branch, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
2
Experimental Transplantation and Immunology Branch, NCI, NIH, Bethesda, MD 20892, USA.
3
Surgery Branch, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma
Vieyra-Garcia et al.
JCI Insight
January 2019
Authors and Affiliates
Vieyra-Garcia P1,2, Crouch JD1, O'Malley JT1, Seger EW1, Yang CH1, Teague JE1, Vromans AM1, Gehad A1, Win TS1, Yu Z3, Lowry EL1, Na JI1,4, Rook AH5, Wolf P2, Clark RA1
1
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
2
Research Unit for Photodermatology, Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.
3
Harvard Medical School, Boston, Massachusetts, USA.
4
Department of Dermatology, Seoul National University Bundang Hospital, Seongnam, South Korea.
5
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor
Leiserson et al.
PLOS ONE
December 2018
Authors and Affiliates
Leiserson MDM1,2, Syrgkanis V1, Gilson A1, Dudik M3, Gillett S1, Chayes J1,3, Borgs C1, Bajorin DF4,5, Rosenberg JE4, Funt S4,5, Snyder A4,6, Mackey L1; 1
Microsoft Research New England, Cambridge, MA, United States of America.
2
University of Maryland, College Park, Department of Computer Science, College Park, MD, United States of America.
3
Microsoft Research New York, New York, NY, United States of America.
4
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America.
5
Department of Medicine, Weill Cornell Medical College, New York, NY, United States of America.
6
Adaptive Biotechnologies, Seattle, WA, United States of America
Radiotherapy induces responses of lung cancer to CTLA-4 blockade
Authors and Affiliates
Formenti SC1, Rudqvist NP2, Golden E2,3, Cooper B4, Wennerberg E2, Lhuillier C2, Vanpouille-Box C2, Friedman K5, Ferrari de Andrade L6,7, Wucherpfennig KW6,7, Heguy A8,9, Imai N10, Gnjatic S10, Emerson RO11, Zhou XK12, Zhang T13, Chachoua A14, Demaria S15,16.
1
Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA. formenti@med.cornell.edu.
2
Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.
3
Department of Radiation Oncology, University of California, San Francisco, CA, USA.
4
Department of Radiation Oncology, New York University School of Medicine, New York, NY, USA.
5
Department of Radiology, New York University School of Medicine, New York, NY, USA.
6
Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
7
Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA, USA.
8
Department of Pathology, New York University School of Medicine, New York, NY, USA.
9
Genome Technology Center, Division of Advanced research Technologies, NYU Langone Health, New York, NY, USA.
10
Tisch Cancer Institute, Hematology/Oncology, Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
11
Adaptive Biotechnologies, Seattle, WA, USA.
12
Division of Biostatistics and Epidemiology, Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, NY, USA.
13
Department of Microbiology and Immunology, Weill Cornell Medicine, New York, NY, USA.
14
Department of Medicine, New York University School of Medicine, New York, NY, USA.
15
Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA. szd3005@med.cornell.edu.
16
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA. szd3005@med.cornell.edu.
Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells
Ruck et al.
Neurology
December 2018
Authors and Affiliates
Ruck T1, Pfeuffer S2, Schulte-Mecklenbeck A2, Gross CC2, Lindner M2, Metze D2, Ehrchen J2, Sondermann W2, Pul R2, Kleinschnitz C2, Wiendl H2, Meuth SG2, Klotz L2.
1
From the Clinic of Neurology with Institute of Translational Neurology (T.R., S.P., A.S.-M., C.C.G., M.L., H.W., S.G.M., L.K.) and Department of Dermatology (D.M., J.E.), University of Münster; and Departments of Dermatology, Venereology, and Allergology (W.S.) and Neurology (R.P., C.K.), University School of Medicine Essen-Duisburg, Essen, Germany. tobias.ruck@ukmuenster.de.
2
From the Clinic of Neurology with Institute of Translational Neurology (T.R., S.P., A.S.-M., C.C.G., M.L., H.W., S.G.M., L.K.) and Department of Dermatology (D.M., J.E.), University of Münster; and Departments of Dermatology, Venereology, and Allergology (W.S.) and Neurology (R.P., C.K.), University School of Medicine Essen-Duisburg, Essen, Germany.
Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors
Chee et al.
BMC Research Notes
December 2018
Authors and Affiliates
Chee J1, Watson MW2, Chopra A2, Nguyen B3, Cook AM4, Creaney J4, Lesterhuis WJ4, Robinson BW4,5, Lee YCG5,6, Nowak AK4,3, Lake RA4, McDonnell AM4
1 National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Nedlands, Western Australia, Australia. jonathan.chee@uwa.edu.au.
2 Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Australia.
3 Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
4 National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Nedlands, Western Australia, Australia.
5 Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
6 Institute of Respiratory Health, School of Medicine, University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables
Erhart et al.
Acta Neuropathologica
December 2018
Authors and Affiliates
Erhart F1,2, Buchroithner J3, Reitermaier R4, Fischhuber K4, Klingenbrunner S4, Sloma I5, Hibsh D5, Kozol R5, Efroni S5, Ricken G6, Wöhrer A6, Haberler C6, Hainfellner J6, Krumpl G4, Felzmann T4, Dohnal AM7, Marosi C8, Visus C4
1-Institute of Neurology, Medical University of Vienna, Währinger Gürtel 18-20, 1097, Vienna, Austria. friedrich.erhart@meduniwien.ac.at.
2-Department of Neurosurgery, Medical University of Vienna, Währinger Gürtel 18-20, 1097, Vienna, Austria. friedrich.erhart@meduniwien.ac.at.
3-University Clinic for Neurosurgery, Kepler University Hospital, Johannes Kepler University, Wagner-Jauregg-Weg 15, 4020, Linz, Austria.
4-Activartis Biotech GmbH, Wilhelminenstraße 91/IIf, 1160, Vienna, Austria.
5-Systems Bio Medicine Lab, Bar Ilan University, 5290002, Ramat Gan, Israel.
6-Institute of Neurology, Medical University of Vienna, Währinger Gürtel 18-20, 1097, Vienna, Austria.
7-Laboratory for Tumor Immunology, CCRI St. Anna Kinderkrebsforschung, Zimmermannplatz 10, 1090, Vienna, Austria.
8-Clinical Division of Medical Oncology, Medical University of Vienna, Währinger Gürtel 18-20, 1097, Vienna, Austria.